Amphastar Pharmaceuticals Inc., sanofi-aventis, Teva cardiovascular news

A U.S. court issued a ruling that, if finalized, would lift the 30-month stay on FDA approval of generic versions of Lovenox enoxaparin from SAN. SAN filed the suit in the U.S. District Court for the Central District of California against Amphastar and TEVA. SAN alleged that the companies infringe its U.S. Patent No. 5,389,618 covering Lovenox. In its ruling, the court granted a motion by TEVA and Amphastar for summary judgment based on inequitable conduct. SAN will appeal if the District Court enters the ruling as final judgment. ...